dorfmanmaster

Gilead in tested channel

Panjang
NASDAQ:GILD   Gilead Sciences, Inc.
GILD has seen positive price action YTD; due to combatting the COVID-19 with their drug Remdesivir.

Yesterday on the news, the trial on humans which was set in China to prove the effectivity of the drug, apparently "failed". However... The price just took us to the lower part of the channel, meaning the Risk-Reward-Ratio is at a good stance.

A close below the 50sma would change the sentiment, and remove us from the channel.

Penafian

Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.